alexa Atrial flutter | Russian Federation| PDF | PPT| Case Reports | Symptoms | Treatment

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Atrial Flutter

  • Atrial flutter

    Atrial flutter is an abnormal cardiac rhythm characterized by rapid, regular atrial depolarizations at a characteristic rate of approximately 300 beats/min and a regular ventricular rate of about 150 beats/min in patients not taking atrioventricular (AV) nodal blockers. It can lead to symptoms of palpitations, shortness of breath, fatigue, or lightheadedness, as well as an increased risk of atrial thrombus formation that may cause cerebral and/or systemic embolization.

  • Atrial flutter

    Atrial flutter occurs in many of the same situations as atrial fibrillation, which is much more common. Atrial flutter may be a stable rhythm or a bridge arrhythmia between sinus rhythm and atrial fibrillation. It may also be associated with a variety of other supraventricular arrhythmias. In atrial flutter, your heart's upper chambers (atria) beat too quickly. This causes the heart to beat in a fast, regular rhythm. Atrial flutter is a type of heart rhythm disorder (arrhythmia) caused by problems in your heart's electrical system. Atrial flutter is similar to atrial fibrillation, a common heart rhythm disorder.

  • Atrial flutter

    Atrial fibrillation and 1-year follow-up data are available for 63,589 patients. The prevalence of AF was, 12.5%, 13.7%, 11.5%, and 6.2% among coronary artery disease, CV disease, peripheral artery disease, and RF-only patients, respectively. Of the 6,814 patients with AF, 6.7% experienced CV death, nonfatal MI, or nonfatal stroke within a year. The annual incidence of nonfatal stroke  and unstable angina was higher, and CV death was more than double, in AF versus non-AF patients. In these patients with or at high risk of atherothrombosis, most patients with AF received antiplatelet agents, but only 53.1% were treated with oral anticoagulants.

Speaker PPTs

High Impact List of Articles

Conference Proceedings